As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers
The Laryngoscope · 2024
DOI: 10.1002/lary.31544 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Laryngoscope, 2024. Verfasst von Natcha Watanapokasin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Xerostomia, Pilocarpine, Head and Neck Neoplasms, Cross-Over Studies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Faculty of Medicine, Chulalongkorn University.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the efficacy of as‐needed pilocarpine for the management of radiation‐induced xerostomia. Additionally, the study sought to assess the side effects associated with an as‐needed regimen.
Methods
A randomized, double‐blinded, placebo‐controlled crossover study was conducted on patients who had undergone radiation therapy for head and neck cancers and developed xerostomia. Participants took pilocarpine or placebo as needed for symptom relief at 2 weeks per treatment, which included a one‐week washout period. The primary outcome measure was the severity of dry mouth symptoms, quantified using the Xerostomia Inventory (XI). The primary outcome was the change in the XI score.
Results
Among the 20 participants who completed the crossover study, there was a significant reduction in XI scores during the treatment phase with pilocarpine compared to the scores during the placebo phase. The mean difference in XI scores was −18.05 (95% CI: −17.17, −6.13, p < 0.001), with a−49.77 ± 3.22% change ( p < 0.001). Only one participant withdrew due to pilocarpine side effects.
Conclusion
As‐needed pilocarpine administration is effective in relieving symptoms of radiation‐induced xerostomia, with fewer side effects and reduced treatment costs compared to fixed‐dose regimens. This study guides the potential shift toward flexible dosing strategies in clinical practice, promoting enhanced patient‐centered, tailored care and adherence. Level of Evidence 2. According to the Oxford Center for Evidence‐Based Medicine 2011 level of evidence guidelines Laryngoscope , 134:4542–4548, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Natcha Watanapokasin, Napadon Tangjaturonrasme
Förderung
- Faculty of Medicine, Chulalongkorn University
Zitieren
APA
Watanapokasin, N., Rawangban, W., & Tangjaturonrasme, N. (2024). As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers. The Laryngoscope. https://doi.org/10.1002/lary.31544
Vancouver
Watanapokasin N, Rawangban W, Tangjaturonrasme N. As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers. The Laryngoscope. 2024. doi:10.1002/lary.31544
BibTeX
@article{Watanapokasin2024,
author = {Watanapokasin, Natcha and Rawangban, Worawat and Tangjaturonrasme, Napadon},
title = {As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31544}
}
EUVIMED